Updated:
Northislet
Northislet is a growth capital investor focused on Life Science and Healthcare investments in the Nordic region. The firm has made 11 investments to date.
Northislet
Northislet is a growth capital investor focused on Life Science and Healthcare investments in the Nordic region. The firm has made 11 investments to date. Its most recent investment was in AAX Biotech, a Seed VC investment made on October 2, 2024.
General information
Firm type
Private Equity
Year founded
2017
AUM
Undisclosed
Location
Region
Europe
Country
Sweden
City
Stockholm
Corporate office
Jan Inghes Torg 28, SE-120 71 Stockholm, Sweden
Additional offices
London, United Kingdom
Sector focus
Frequently asked questions
What does Northislet invest in?
Northislet focuses exclusively on life-science companies in the Nordic region. It targets small to mid-sized growth businesses that provide tools, diagnostics, therapeutics, and services to the pharmaceutical and healthcare industries. The firm invests in both listed and unlisted companies and has no ownership restrictions.
How does Northislet structure its investments across company stages?
The firm organizes its portfolio into three stages it calls Islets: Early Stage for high-risk, early-stage investments including cancer detection and precision medicine; Operational for commercial-stage companies requiring active governance; and Long-term for mature assets. This structure allows Northislet to diversify risk across binary-outcome science and more stable, infrastructural life-science businesses.
Does Northislet operate with a defined exit timeline?
No. Northislet explicitly states it has no defined exit timeline and takes a long-term approach, supporting companies through different phases of their life cycle. This permanent-capital posture distinguishes it from traditional private-equity funds that typically have 10–12 year fund lives.
Which geographies does Northislet cover?
The investment mandate covers the Nordic region — Sweden, Norway, Denmark, Finland, and Iceland. Northislet operates from its Stockholm headquarters with an additional office in London, though the London office does not appear to be an investment origination hub.
Who runs investment decisions at Northislet?
Northislet does not publicly disclose its principals or investment committee members on its website or LinkedIn. The firm's governance and decision-making structure remains opaque to external allocators as of mid-2026.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: